Edit/Futu Information Udon
Futu News reported on January 17 that Shiyao had a sharp rise near the midday closing. As of press release, it had risen 5.78% to HK$19.04, with a turnover of HK$789 million.
Market source: Futu Securities
Tenders for the second round of collection were opened in Shanghai today. A total of 33 varieties of drugs, including 50 product regulations, participated in volume procurement this time.
In this round of collection, the bidding companies for albumin paclitaxel were Henrui, Shiyao, Qilu, and Xinji, with prices of 780, 747, 1,828, and 1,150 yuan/stick, respectively. Qilu was out, and the remaining three companies were shortlisted.
The bidding companies for acarbose include Huadong Huadong, Zhongmei Huadong, Luye Pharmaceutical, and Bayer, a subsidiary of Huadong Pharmaceutical. The prices of the three companies were 13.96 yuan, 9.6 yuan, and 5.42 yuan respectively. The specifications were 50mg/30 tablets. The converted price of a single tablet by Bayer is 0.1807 yuan, which is nearly 80% lower than the stipulated maximum valid declaration price of 0.8353. As Huadong Pharmaceutical was out of the market, diving plummeted 9%.
Market source: Futu Securities